Objective: To assess the prevalence of overweight and obesity in children living in the Netherlands and compare the findings with the Third and Fourth National Growth Studies carried out in 1980 and 1997, respectively. Design and methods: Data were obtained from the child health care system. International cut-off points for body mass index (BMI) were used to determine overweight and obesity. Cases were weighted for ethnicity and municipality size in such a way that the sample matched the distribution in the general population. The LMS method was used to calculate the age-related distribution of BMI, and the prevalence was calculated from the fitted distribution. Patients: Data on 90 071 children aged 4-16 years were routinely collected by 11 community health services during [2002][2003][2004]. Results: On average, 14.5% of the boys and 17.5% of the girls were overweight (including obesity), which is a substantial increase since 1980 (boys 3.9%, girls 6.9%) and 1997 (boys 9.7%, girls 13.0%). Similarly, 2.6% of the boys and 3.3% of the girls aged 4-16 years were obese, which is much higher than in 1980 (boys 0.2%, girls 0.5%) and 1997 (boys 1.2%, girls 2.0%). At the age of 4, 12.3% of the boys and 16.2% of the girls were already overweight. Conclusions: The prevalence of overweight and obesity in the Netherlands is still rising, and at an even faster rate than before. Evidence-based interventions are needed to counter the obesity epidemic, and there is an urgent need for pre-school intervention programmes.
O verweight is a rapidly growing global public health problem. Overweight and obesity increase the risk of early mortality and severe illnesses, such as heart and vascular diseases, diabetes and psychosocial problems. [1] [2] [3] [4] [5] Awareness of obesity in the Netherlands has increased, especially after the results of the Fourth National Growth Study in 1997 showed a substantial increase in the prevalence of overweight and obesity since 1980. 6 7 It is not known whether, and if so, how the situation has changed since 1997. The aim of this study was to determine the prevalence of overweight and obesity in 2003, and to compare the results to those of earlier studies carried out in 1980 and 1997.
METHODS
The child health care system in the Netherlands routinely monitors the health of approximately 95% of all 0-19-year-old children living in the Netherlands. 8 Local community health services examine children aged 4-19 years, and a number of these organisations maintain an electronic record for each child. We obtained from these records data on height, weight, age, gender, and postal code or municipality of residence. Since the child health care system uses standardised methods to measure children, we did not include data on children who were examined on indication.
The body mass index (BMI) of the children was calculated, and they were classified as normal (including underweight), overweight (including obesity) or obese, based on internationally accepted cut-off points. 9 The results are presented according to gender and age. Because the sample was not random, it contained a relatively high number of children from large cities and from Turkish and Moroccan ethnic minorities, populations which are known have a higher prevalence of overweight. 10 The sample was therefore reweighed in such a way that the proportion of cases per combination of city size and ethnicity equalled that in the population of all children living in the Netherlands on January 1, 2003. 11 The LMS model of Cole and Green was used to fit the age-conditional distribution of BMI for all children living in the Netherlands separately for boys and girls.
12 P-splines were used to smooth the distribution over age, the calculations were carried out using the R-function GAMLSS 13 and the worm plot was used to assess the quality of the solution. 14 The prevalence of overweight and obesity according to age and gender was calculated from the fitted L, M and S curves.
The prevalence of overweight and obesity in 1997 for all children living in the Netherlands was calculated as a weighted average of the published Dutch, Moroccan and Turkish prevalences. 10 The weights used were 0.933, 0.031 and 0.036, More girls than boys were overweight and obese at nearly all ages and during all periods. In 1997, a peak occurred around the age of 6, and the prevalence was lower for older children. In 2003, the prevalence at the age of 6 was similar to the peak in 1997, but the peak in 2003 shifted towards the age of 8 (boys 18.7%, girls 24.4%). The differences in prevalence are fairly large during puberty. Children aged 6 in 1997 were approximately 12 years of age in 2003. By shifting the entire 1997 prevalence curves towards the right by 6 years, we can compare the prevalence within the same birth cohort at different time points. It appears that for nearly all birth cohorts the prevalence in 2003 is equal to or higher than that in 1997. The generation of children born around the year 1995 seems to be particularly at risk of developing overweight and obesity. Note that in 1997, this generation had about the same prevalence as the 2-year-olds in 1980. The increase must thus have occurred between the ages of 2 and 8. Table 2 shows the estimated prevalences in 1980, 1997 and 2003, with all ages combined. The prevalence of overweight and obesity rose between 1980 and 1997, and rose even faster between 1997 and 1980 (cf fig 3) . For boys, the rate of increase in the prevalence of overweight between 1980 and 1997 was approximately +0.34% per year, whereas between 1997 and 2003 it was +0.80% per year. For girls the rate of increase was +0.36% and +0.75% per year, respectively. With regard to obesity, the rate of increase for boys was +0.06% and +0.23% per year, and for girls it was +0.09% and +0.22% per year. The rate of increase generally doubled or tripled between 1997 and 2003.
DISCUSSION
The 1997 study reported a large secular increase in the prevalence of overweight since 1980. The 2003 study indicates that this trend is continuing at an even faster rate. This finding is in line with results in other European countries. 17 In 2003, the 1418  4089  126  1288  1857  12  1  2  2  99  146  36  1  9077  Eemland  30  3074  2968  207  0  0  0  0  271  3084  2129  190  0  11 953  Eindhoven  10  1108  604  0  0  6  906  746  1195  1212  147  8  0  5942  Fryslan  0  0  0  0  0  102  5269  4125  414  2  0  0  0  9912  Groningen  31  625  94  2  14  422  140  2  0  0  0  0  0  1330  Kennemerland 68  2740  1455  177  15  59  1992  1520  180  882  1845  479  59  11 471  Nijmegen  62  1671  394  9  1  22  801  969  1169  966  96  3  0  6163  OZ Limburg  71  1476  680  27  176  2289  710  55  148  895  1192  227  26  7972  Utrecht  33  1950  1977  202  36  1266  1484  331  948  1549  389  36  2  10 203  Z-H Noord  51  1663  627  40  31  100  595  353  56  797  1008  162  2  5485  Z-H Zuid  7  1024  1182  1365  1607  184  712  1057  167  1082  1781  380  15  10 563  Total  1781  19 420  10 107  3317  3737  4462  12 610  9160  4550  10 568  8733  1521  105 prevalence of overweight in boys aged 4-16 years varied from 12.3% to 18.7% (average 14.5%), and in girls varied from 15.5 to 24.4% (average 17.5%). The prevalence of obesity was also higher among girls: 2.4% to 5.4% (average 3.3%) for girls compared to 2.1% to 3.9% (average 2.6%) for boys. A particularly worrying aspect is that the dip in the prevalence after the age of 6 that was found in 1997 seems to have vanished in 2003. In 1997, two possible reasons were put forward to explain this: either the prevalence for 5-7-year-olds was higher because the cut-off points for these age-groups were somehow too low (methodological effect) or the cohort of children born since 1990 is structurally different (ie, heavier) than previous cohorts (cohort effect). 7 The 2003 results point strongly towards the second explanation of a structural cohort effect. Given the present analysis, a methodological effect seems highly unlikely.
It is not known what causes the difference in prevalence between girls and boys, which already exists before they go to school. In order to prevent young girls and boys (up to the age of 4) from becoming overweight, there is an urgent need for pre-school intervention programmes.
Two methods can be used to reliably compare the prevalence in regions of the Netherlands, or in other countries, with the prevalence curves presented here. The first option is to apply the methods used in the present study, including the LMS method, and to compare the resulting age-smoothed prevalence curves directly. The second option is to classify children as normal, overweight or obese, based on the internationally accepted cutoff points for BMI, and then calculate the prevalence and the 95% confidence intervals per age group. An overlap of the confidence interval with the Dutch prevalence at the relevant ages would indicate that the difference between the observed prevalence and the expected prevalence could be due to chance.
CONCLUSION
The global obesity epidemic is also occurring in the Netherlands, and evidence-based interventions are needed to halt the increase. The Dutch child health care system plays a vital role, because it examines all children living in the Netherlands and therefore provides good opportunities for intervention. Preschool intervention programmes may be useful. What is already known on this topic N Overweight is a growing global public health problem. N Overweight and obesity increase the risk of early mortality and severe illness. N More girls than boys are overweight and obese. N There is an urgent need for pre-school intervention programmes.
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